Several key concepts have emerged from the reviews and expert discussions included in this supplement, which could allow the translation of our current knowledge of HBV heterogeneity to the personalized care of patients with chronic hepatitis B (CHB).
The first concept concerns the ability to distinguish between HBV infection per se and CHB infection, the only clinical condition eligible for antiviral therapy. Treatment of HBV infection in the absence of HBVinduced liver disease is counterproductive and has a negative cost-benefit ratio. It is common experience that the treatment of highly viraemic hepatitis B e antigen (HBeAg)-positive HBV carriers without evidence of liver disease results in non-response or minimal response in the majority of patients, regardless of the antiviral drug used. Furthermore, although treatment with pegylated interferons (PEG-IFNs) in such carriers might be ineffective, the use of newer more potent nucleoside/nucleotide analogues (NAs) might actually be dangerous, resulting in the selection of drugresistant mutants as the consequence of a largely inefficient inhibition of viral replication. HBeAg-negative hepatitis B surface antigen (HBsAg) carriers represent the majority of cases of HBV infection worldwide. The clinical condition of these patients ranges from inactive carrier status through to the full spectrum of liver disease, and they show varied rates of disease progression and survival. Although efficacious antiviral treatments are available, they are costly and might be associated with potential issues such as side effects or resistance development; therefore, in everyday clinical practice, it is important to identify those patients who require and will benefit from treatment. However, differential diagnosis between early asymptomatic HBeAg-negative, HBeAg-antibody-positive CHB and the inactive HBsAg carrier state is problematic because HBeAg-negative CHB is characterized by wide fluctuations in viral replication and biochemical activity. The monitoring of serum HBV DNA by sensitive, quantitative PCR assays and alanine aminotransferase (ALT) measurements over a period of at least 1 year has been required to warrant an accurate differential diagnosis, clearly an unsatisfactory situation. A major contribution to the management of HBeAg-negative HBV carriers, and to the most accurate diagnosis of the phase of HBV infection in asymptomatic HBeAg-negative HBsAg carriers has come from the recently proposed single-point combined quantification of HBV DNA and HBsAg.
Currently, five NAs have been approved for the treatment of CHB (lamivudine, adefovir, entecavir, telbivudine and tenofovir disoproxil fumarate); however, although newer NAs show higher antiviral potency and better resistance profiles during relatively short followups, available data indicate that life-long treatment is still needed in most patients. Thus, if patients are to undergo life-long therapy there is a need for predictive tests for renal and bone toxicity with adefovir and tenofovir disoproxil fumarate, respectively, and longer term evidence-based data on safety and resistance. Antiviral resistance remains a major risk for NAs and the highest rate of cure with a finite course of PEG-IFN remains approximately 25%; thus, it is important that we aim to increase the potential for success using available drugs by developing new and more personalized treatment regimens. An important and poorly studied factor in achieving initial virological response and in maintaining viral suppression during continued NA treatment is adherence to medication. Attention should be given to designing strategies for counselling and for monitoring adherence to NA therapy to enhance response. On the issue of resistance, various strategies are available to reduce the risk of resistance to antiviral drug regimens including: initiation of treatment with a potent drug that has a high genetic barrier to resistance, initiation of treatment with a combination of drugs, and modification of treatment in patients with suboptimal viral suppression. One important strategy to optimize PEG-IFN therapy is to individualize treatment on the basis of baseline and on-treatment virological and biochemical profiles. This approach includes timing of the PEG-IFN course (available data suggest that low baseline HBV DNA levels and high ALT values, that is, hepatitis flares, are associated with higher changes of response), and tailoring treatment duration on the basis of on-treatment HBV DNA and HBsAg decrease. Preliminary data show different rates of response to PEG-IFN monotherapy and PEG-IFN-NA combination therapies according to HBV genotype. Future studies will be required to specifically address the issue of genotype and its influence on timing of monitoring and cutoff levels for on-treatment HBV DNA and HBsAg decrease to support appropriately tailored decision making in patients infected with different HBV genotypes. Another very important issue will be the differentiation of optimal therapeutic strategies and monitoring criteria to aid treatment decision making in HBeAg-positive and HBeAg-negative CHB.
Preliminary clinical trials of combination therapies raise the hope of significantly higher rates of efficacy and lower durations of treatment, and support a possible therapeutic synergy between the specific activities of PEG-IFNs (immune modulation) and NAs (inhibition of viral replication). Studies also suggest that new therapeutic approaches using intermittent phases of monotherapy using PEG-IFNs or NAs with intervening short courses of combination therapy could be effective. Anecdotal observations support this hypothesis, showing that patients receiving treatment with both PEG-IFNs and NAs achieve efficacious control of HBV infection and eventually clear HBsAg. On the basis of these preliminary data, one potential strategy for study is the use of a lead-in phase of PEG-IFN therapy in treatment-naive, HBeAg-negative CHB patients. After 12-24 weeks of combined HBV DNA and HBsAg monitoring, further therapeutic decisions could be tailored according to the patient's on-treatment response classified in one of three major categories: non-responders (<0.5 log 10 IU/ml decrease in HBsAg together with <1 log 10 copies/ml decrease of HBV DNA versus baseline), fast responders (≥0.5 log 10 IU/ml decrease of HBsAg together with ≥1 log 10 copies/ml decrease of HBV DNA versus baseline) or slow responders (any response between the first two categories). Based on response, further treatment could include continuation of standard length PEG-IFN monotherapy in responders, or adding on or switching to NAs in non-responders, whereas longer treatment durations with PEG-IFN or other alternative strategies might be offered to the intermediate, partial responder.
Future studies should investigate the potential of longer term, but finite curative treatments using both PEG-IFNs and NAs more appropriately, with the aim of achieving more consistent therapeutic results, particularly in difficult-to-treat cases such as genotype-D-infected patients. To further investigate how best to combine PEG-IFNs and NAs, future clinical trials will be required to investigate new combination strategies (including sequential therapies and the use of pulses of PEG-IFN therapy) during long-term NA therapy to decrease overall treatment duration, improve tolerability and reduce resistance. Finally, because a definitive cure of liver disease in the patient with CHB can be achieved only if the therapeutic intervention is provided before the establishment of cirrhosis, special efforts need to be aimed at the development of strategies for the treatment of patients in the earlier phases of liver disease to ensure the best treatment success.
